(391) Engineered Nanovaccines for STING-Activated Antigen Cross-Presentation in Cancer Immunotherapy
Introduction: Cancer immunotherapy relies on antigen presentation by type 1 conventional dendritic cells (cDC1), which are key to cross-priming CD8+ T cells for effective tumor immunity. However, their selective activation remains challenging. A dendritic cell-derived nanovaccines incorporating CLEC9A-specific antibodies, tumor antigens, and STING agonists enhances targeted delivery, facilitates lysosomal escape, and amplifies immune activation, showing strong potential for tumor suppression, metastasis inhibition, and improved efficacy with immune checkpoint blockade.
Learning Objectives:
Learn how cDC1 targeting via CLEC9A enhances antigen cross-presentation and T cell activation.
Understand STING activation’s role in type I IFN production and antitumor immunity.
Evaluate the synergy of nanovaccine therapy with αPD-1 in tumor inhibition.
